For research use only. Not for therapeutic Use.
Misetionamide is an orally oxathiazin-like compound. Misetionamide is a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor with antineoplastic activity. Misetionamide can be used for the research of cancer[1].
Misetionamide (OTD) (0-2000 μM; 0-72 h) induces cell death in TNBC cells[2].
Misetionamide (OTD) (0-2000 μM; 12 h) inhibits TNBC cells proliferation[2].
Misetionamide (OTD) (0-1000 μM; 18 h) induces necrosis and apoptosis in TNBC cells[2].
Misetionamide (OTD) (250-1000 μM; 18 h) induces cell death by a ROS-dependent mechanism in TNBC cells[2].
| Catalog Number | I043404 |
| CAS Number | 856785-75-6 |
| Synonyms | 1,4,3-oxathiazinane 4,4-dioxide |
| Molecular Formula | C3H7NO3S |
| Purity | ≥95% |
| InChI | InChI=1S/C3H7NO3S/c5-8(6)2-1-7-3-4-8/h4H,1-3H2 |
| InChIKey | GHDARLKSYBCZRE-UHFFFAOYSA-N |
| SMILES | C1CS(=O)(=O)NCO1 |
| Reference | [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information. 2022. 36(2):337. [2]. Jinih M, et al. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells. Anticancer Res. 2021 May;41(5):2247-2256. |
